Literature DB >> 32016106

The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth.

Joseph D Frasca1, Adam S Cheifetz2.   

Abstract

Entities:  

Year:  2019        PMID： 32016106      PMCID： PMC6976392          DOI： 10.21037/atm.2019.12.86

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  37 in total

1.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

2.  Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.

Authors:  Chao Chen; Abraham G Hartzema; Hong Xiao; Yu-Jung Wei; Naueen Chaudhry; Ofor Ewelukwa; Sarah C Glover; Ellen M Zimmermann
Journal:  Inflamm Bowel Dis       Date:  2019-07-17       Impact factor: 5.325

3.  Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.

Authors:  Konstantinos Papamichael; Karen A Chachu; Ravy K Vajravelu; Byron P Vaughn; Josephine Ni; Mark T Osterman; Adam S Cheifetz
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-30       Impact factor: 11.382

4.  Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease.

Authors:  Francesc Casellas; Manuel Barreiro de Acosta; Marta Iglesias; Virginia Robles; Pilar Nos; Mariam Aguas; Sabino Riestra; Ruth de Francisco; Michel Papo; Natalia Borruel
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-07       Impact factor: 2.566

5.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-14       Impact factor: 22.682

6.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

7.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.

Authors:  Kathrine Frey Frøslie; Jørgen Jahnsen; Bjørn A Moum; Morten H Vatn
Journal:  Gastroenterology       Date:  2007-06-02       Impact factor: 22.682

8.  Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.

Authors:  Yoon Suk Jung; Minkyung Han; Sohee Park; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2019-11-01       Impact factor: 3.199

9.  Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.

Authors:  Millie D Long; Timothy W Smith; Marco Dibonaventura; David Gruben; Danielle Bargo; Leonardo Salese; Daniel Quirk
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

10.  Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.

Authors:  R Panaccione; J-F Colombel; W J Sandborn; G D'Haens; Q Zhou; P F Pollack; R B Thakkar; A M Robinson
Journal:  Aliment Pharmacol Ther       Date:  2013-09-22       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.